Bergen, Norway

BerGenBio is a clinical-stage, biopharmaceutical company based in Bergen, Norway and Oxford, UK. It is developing innovative therapies for aggressive cancers by way of inhibiting the Axl signalling pathway. The lead oncology compound, bemcentinib, is in multiple Phase II trials.

Investment Perspective

BerGenBio has reported promising results from its broad Phase II programme with bemcentinib focussed on acute myeloid leukaemia (AML) and non-small cell lung cancer (NSCLC) throughout 2018. Most notable were the data from the study in NSCLC in combination with the PD‑1 inhibitor pembrolizumab, in which patients with PD-L1 negative tumours responded well to therapy. The results thus far indicate the importance of biomarkers to identify those patients with Axl+ tumours, who are most likely to benefit from bemcentinib. The company is planning a series of randomised Phase II trials to confirm the findings to date, which are due to start in H219. BerGenBio also has two other products that have just entered clinical development. We value the company at NOK3.14bn, or NOK57.45/share.

Market information

SymbolPrimary exchangeCurrency
Last PriceMarket Cap
52 Week Low52 Week High


Efficacy endpoint met in Phase II AML study
Lighthouse | 02 Apr 2019
Further support for bemcentinib’s broad potential from preclinical data at AACR
Lighthouse | 01 Apr 2019
Resolution of Rigel arbitration reduces uncertainty
Lighthouse | 01 Mar 2019

Recent News

Phase II bemcentinib + Keytruda NSCLC trial extended
02 Apr 2019
Preclinical data at AACR reinforces bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance
02 Apr 2019
Bemcentinib with low-dose chemotherapy achieves efficacy endpoint in AML
01 Apr 2019
Key Executive Team and Board Appointments
14 Mar 2019